Trials / Completed
CompletedNCT06680440
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of ASC30 Tablets and ASC30 Tablets A1 in Participants With Obesity
A Phase I Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASC30 Tablets in Participants With Obesity
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- Ascletis Pharma (China) Co., Limited · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This is a phase I, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, efficacy, food effect of ASC30 Tablets or ASC30 Tablets A1 in participants with obesity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ASC30 | Tablet, QD |
| OTHER | Placebo | Tablets, QD |
Timeline
- Start date
- 2024-08-26
- Primary completion
- 2025-04-03
- Completion
- 2025-04-03
- First posted
- 2024-11-08
- Last updated
- 2025-05-20
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06680440. Inclusion in this directory is not an endorsement.